Amylyx Pharmaceuticals Appoints Camille L. Bedrosian, MD, as Chief Medical OfficerBusiness Wire • 11/28/23
RELYVRIO® and AMX0114 Data to be Presented at 34th International Symposium on ALS/MNDBusiness Wire • 11/27/23
Amylyx Pharmaceuticals to Participate at the 6th Annual Evercore ISI HealthCONx ConferenceBusiness Wire • 11/21/23
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Amylyx Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 11/16/23
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Amylyx Pharmaceuticals, Inc. (AMLX)Business Wire • 11/14/23
Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 ReleaseZacks Investment Research • 11/02/23
Amylyx Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 9, 2023Business Wire • 11/02/23
Amylyx Pharmaceuticals to Present Clinical Trial Design of ORION, a Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy (PSP), at the Neuro2023 PSP and CBD International Research SymposiumBusiness Wire • 10/19/23
Amylyx Pharmaceuticals shares fall after ALS treatment is rejected by European regulatorMarket Watch • 10/13/23
Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination ProcessBusiness Wire • 10/13/23
Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial ControlBusiness Wire • 10/10/23
Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in FranceBusiness Wire • 10/05/23
RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) MeetingBusiness Wire • 10/02/23
Amylyx Pharmaceuticals, Inc. (AMLX) Surpasses Q2 Earnings and Revenue EstimatesZacks Investment Research • 08/10/23